A Phase 4 interventional study of CP-690,550 and Methotrexate in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 136 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-04.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is one of 2 that started in 2016, is one of 12 in phase 4, and was the 27th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 694 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 8th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2016, is one of 17 in phase 4, and was the 120th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of methotrexate treatment.
Key Inclusion Criteria
Have a score of 6 or greater on the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis at and/or prior to Screening Visit.
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label tofacitinib tablet and blinded methotrexate capsule
Drug: CP-690,550 · Drug: Methotrexate
open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
Drug: Placebo
During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose. During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Also known as: tofacitinib
During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose. During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
Double Blind Phase: Change From Randomization in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 48
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, ESR (millimeters per hour \[mm/hr\]) and participant global assessment of arthritis (PtGA) on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (\<=) 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) less than (\<) 2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm; ln = natural logarithm, sqrt = square root of.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 48
Double Blind Phase: Change From Randomization in DAS28-4 ESR at Week 36
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 millimeter (mm) VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (\<=) 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) less than (\<) 2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm; ln = natural logarithm, sqrt = square root of.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 36
Double Blind Phase: Change From Randomization in DAS28-4 (C-reactive Protein [CRP]) at Weeks 36 and 48
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (milligrams per liter \[mg/L\]) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 implied low disease activity and \> 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \< 2.6 implied remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root of.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Change From Randomization in Clinical Disease Activity Index (CDAI) at Weeks 36 and 48
CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and physician global assessment of arthritis (PhyGA). PtGA and PhyGA both were assessed on 0-10 centimeter (cm) VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicated low disease activity and a score of \<= 2.8 indicated remission. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Change From Randomization in Simplified Disease Activity Index (SDAI) at Weeks 36 and 48
SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Percentage of Participants With Low Disease Activity (LDA) Assessed by DAS28-4 (ESR) Less Than or Equal to (<=) 3.2 at Weeks 36 and 48
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm; ln = natural logarithm, sqrt = square root of.
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With LDA Assessed by DAS28-4 (CRP) <=3.2 at Weeks 36 and 48
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root of.
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With LDA Assessed by CDAI <=10 at Weeks 36 and 48
CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicated low disease activity and a score of \<= 2.8 indicated remission. Percentage of participants with CDAI \<=10 were reported. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With LDA Assessed by SDAI <=11 at Weeks 36 and 48
SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicated low disease activity and a score of \<=3.3 indicated remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Weeks 36 and 48
ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), CRP (in mg/dL), and PtGA (VAS: 0 cm \[very well\] to 10 cm \[worst\], higher scores indicated worse health condition) and all scores were \<=1.
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With Remission Assessed by DAS28-4 (ESR) Less Than [<] 2.6 at Weeks 36 and 48
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm. Percentage of participants with DAS remission (DAS28-4-ESR\<2.6) were reported in this outcome measure.
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With Remission Assessed by DAS28-4 (CRP) <2.6 at Weeks 36 and 48
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/l +1) + 0.014\*PtGA in mm+ 0.96. Percentage of participants with DAS remission (DAS28-4-CRP\<2.6) were reported in this outcome measure.
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With Remission Assessed by CDAI <=2.8 at Weeks 36 and 48
CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicated low disease activity and a score of \<= 2.8 indicated remission. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants With Remission Assessed by SDAI <=3.3 at Weeks 36 and 48
SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).
Time frame: Weeks 36 and 48
Double Blind Phase: Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%) (ACR20) Response at Weeks 36 and 48
Participants with 20% improvement in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).
Time frame: Baseline (Day 1), Weeks 36 and 48
Double Blind Phase: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Weeks 36 and 48
Participants with 50% improvement in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).
Time frame: Baseline (Day 1), Weeks 36 and 48
Double Blind Phase: Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Weeks 36 and 48
Participants with 70% improvement in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).
Time frame: Baseline (Day 1), Weeks 36 and 48
Double Blind Phase: Change From Randomization in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 36 and 48
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities.. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Change From Randomization in the Short Form 36 (SF-36) Health Survey 8 Domain Scores at Weeks 36 and 48
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health perception. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were summarized to derive the 2 component scores (physical component scores \[PCS\], mental component scores \[MCS\]) ranging from 0 (worst) to 100 (best), where higher PCS/MCS indicated good health condition.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Change From Randomization in the SF-36 Health Survey Component Scores at Weeks 36 and 48
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health perception. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were summarized aggregated to derive the two 2 component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher PCS/MCS indicated good health condition.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Change From Randomization in the Work Productivity and Activity Impairment (WPAI) Scores at Week 36 and 48
WPAI is 6-question participant rated questionnaire to determine the impact of rheumatoid arthritis and yields 4 types of outcomes: absenteeism (work time missed), presenteeism (impairment while working), work productivity loss (overall work impairment), and daily activity impairment (activity impairment) for a period of 7 days prior to a visit. These 4 outcomes are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 36 and 48
Double Blind Phase: Change From Randomization in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Weeks 36 and 48
EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. 3 possible answers for mobility: 1=no problem in walking, 2=moderate problems in walking, 3= confined to bed; self-care: 1=no problem, 2=moderate problems, 3= unable to wash/dress; usual activities: 1=no problem, 2=moderate problems, 3= unable to do usual activities; pain and discomfort: 1=no pain or discomfort, 2=moderate pain or discomfort, 3= extreme pain or discomfort; anxiety and depression: 1=not anxious or depressed, 2=moderately anxious or depressed, 3= extremely anxious or depressed. The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Change From Randomization in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Weeks 36 and 48
The FACIT-Fatigue scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (maximum fatigue) to 4 (no fatigue), higher scores indicate less fatigue. Total FACIT-fatigue score was obtained by addition of scores from 13 items, giving a possible overall range from 0 (maximum fatigue) to 52 (no fatigue). Higher FACIT-fatigue scores indicated lower level of fatigue, better participant status.
Time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48
Double Blind Phase: Percentage of Participants Achieving an Improvement of at Least 0.22 Units in HAQ-DI at Weeks 36 and 48
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities.. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Percentage of participants with an improvement of at least 0.22 units in HAQ scores from baseline (Day 1) to Weeks 36 and 48 were reported in this outcome measure.
Time frame: Baseline (Day 1), Weeks 36 and 48
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 52 (up to 28 days after last dose) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.
Time frame: For OL Phase: Baseline up to Week 24; For DB Phase: Week 24 up to Week 52 (up to 28 days after last dose)
Number of Participants With Abnormal Laboratory Parameters
Abnormality criteria: Hemoglobin (Hb),Hematocrit,Erythrocytes(Ery): \<0.8\*LLN;Ery. Mean corpuscular volume \<0.9\*lower limit of normal (LLN), \>1.1\*upper limit of normal (ULN); Platelets:\<0.5\*LLN,\>1.75\*ULN;WBCs:\<0.6\*LLN,\>1.5\*ULN; Lymphocytes/WBCs, Neutrophils/WBCs:\<0.8\*LLN,\>1.2\* ULN;Basophils,Basophils/WBCs,Eosinophils,Eosinophils/WBCs,Monocytes, Monocytes/WBCs: \>1.2\*ULN;Prothrombin Time, Prothrombin Intl. Normalized Ratio:\>1.1\*ULN; ESR:\>1.5\*ULN; Bilirubin,Direct Bilirubin,Indirect Bilirubin: \>1.5\*ULN; Aspartate Aminotransferase (AT),Alanine AT,Gamma Glutamyl Transferase,Alkaline Phosphatase:\>3.0\*ULN; Protein, Albumin: \<0.8\*LLN, \>1.2x ULN; Blood Urea Nitrogen, Creatinine, Triglycerides: \>1.3\*ULN;HDL Cholesterol:\<0.8\*LLN;Sodium \<0.95\*LLN, \>1.05\*ULN;Potassium, Chloride, Calcium, Bicarbonate: \<0.9\*LLN, \>1.1\*ULN; Glucose: \<0.6\*LLN, \>1.5\*ULN; Creatine Kinase: \>2.0\*ULN; Cholesterol:\>1.3\*ULN;Specific Gravity:\<1.003;pH:\<4.5; urine glucose,Ketones,urine protein,urine Hb,WBCs Esterase: \>=1.
Time frame: For OL Phase: Baseline up to Week 24; For DB Phase: Week 24 up to Week 48
| Milestone | Open Label: Tofacitinib 11 mg + Methotrexate | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|---|
| Started | 694 | 0 | 0 |
| Completed | 623 | 0 | 0 |
| Not completed | 71 | 0 | 0 |
| Withdrew: Adverse event | 39 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 0 | 0 |
| Withdrew: Insufficient clinical response | 7 | 0 | 0 |
| Withdrew: Medication error,no linked adverse event | 2 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 |
| Withdrew: Other | 4 | 0 | 0 |
| Milestone | Open Label: Tofacitinib 11 mg + Methotrexate | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|---|
| Started | 0 | 267 | 266 |
| Treated | 0 | 264 | 266 |
| Completed | 0 | 238 | 247 |
| Not completed | 0 | 29 | 19 |
| Withdrew: Adverse event | 0 | 6 | 6 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Screen failure | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 2 |
| Withdrew: Other | 0 | 2 | 5 |
| Withdrew: Insufficient clinical response | 0 | 6 | 1 |
| Withdrew: Protocol violation | 0 | 5 | 2 |
| Withdrew: Randomized but not treated | 0 | 3 | 0 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, ESR (millimeters per hour \[mm/hr\]) and participant global assessment of arthritis (PtGA) on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (\<=) 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) less than (\<) 2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm; ln = natural logarithm, sqrt = square root of.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Double Blind Phase: Change From Randomization in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 48 | 0.33 ± 0.07 | 0.03 ± 0.07 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 millimeter (mm) VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (\<=) 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) less than (\<) 2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm; ln = natural logarithm, sqrt = square root of.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Double Blind Phase: Change From Randomization in DAS28-4 ESR at Week 36 | 0.40 ± 0.07 | 0.18 ± 0.07 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (milligrams per liter \[mg/L\]) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 implied low disease activity and \> 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \< 2.6 implied remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root of.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36 | 0.38 ± 0.06 | 0.13 ± 0.06 |
| Change at Week 48 | 0.29 ± 0.06 | 0.01 ± 0.06 |
CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and physician global assessment of arthritis (PhyGA). PtGA and PhyGA both were assessed on 0-10 centimeter (cm) VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicated low disease activity and a score of \<= 2.8 indicated remission. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36 | 3.58 ± 0.49 | 1.84 ± 0.48 |
| Change at Week 48 | 2.97 ± 0.48 | 0.84 ± 0.47 |
SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36 | 3.83 ± 0.52 | 1.88 ± 0.51 |
| Change at Week 48 | 3.16 ± 0.50 | 0.94 ± 0.49 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm; ln = natural logarithm, sqrt = square root of.
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 42.42 | 48.12 |
| Week 48 | 45.08 | 49.62 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root of.
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 65.53 | 70.68 |
| Week 48 | 65.91 | 74.44 |
CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicated low disease activity and a score of \<= 2.8 indicated remission. Percentage of participants with CDAI \<=10 were reported. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 66.29 | 73.68 |
| Week 48 | 65.15 | 77.07 |
SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicated low disease activity and a score of \<=3.3 indicated remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 66.29 | 73.31 |
| Week 48 | 66.29 | 76.32 |
ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), CRP (in mg/dL), and PtGA (VAS: 0 cm \[very well\] to 10 cm \[worst\], higher scores indicated worse health condition) and all scores were \<=1.
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 15.53 | 24.06 |
| Week 48 | 22.35 | 23.68 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. DAS28-4 (ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*In(ESR in mm/hour) + 0.014\*PtGA in mm. Percentage of participants with DAS remission (DAS28-4-ESR\<2.6) were reported in this outcome measure.
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 20.45 | 28.57 |
| Week 48 | 23.86 | 30.08 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/l +1) + 0.014\*PtGA in mm+ 0.96. Percentage of participants with DAS remission (DAS28-4-CRP\<2.6) were reported in this outcome measure.
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 50.00 | 55.64 |
| Week 48 | 50.38 | 54.51 |
CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicated low disease activity and a score of \<= 2.8 indicated remission. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 23.48 | 32.33 |
| Week 48 | 28.41 | 30.83 |
SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm \[very well\] to 10 cm \[worst\]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 22.73 | 31.58 |
| Week 48 | 28.79 | 31.95 |
Participants with 20% improvement in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 73.86 | 80.83 |
| Week 48 | 73.11 | 79.70 |
Participants with 50% improvement in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 53.79 | 66.54 |
| Week 48 | 55.30 | 67.29 |
Participants with 70% improvement in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 35.61 | 40.98 |
| Week 48 | 37.88 | 42.86 |
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities.. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36 | 0.10 ± 0.03 | 0.01 ± 0.03 |
| Change at Week 48 | 0.01 ± 0.03 | 0.00 ± 0.03 |
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health perception. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were summarized to derive the 2 component scores (physical component scores \[PCS\], mental component scores \[MCS\]) ranging from 0 (worst) to 100 (best), where higher PCS/MCS indicated good health condition.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36: Physical Functioning | -1.32 ± 0.50 | -0.88 ± 0.49 |
| Change at Week 36: Role Physical Score | -1.69 ± 0.48 | -0.02 ± 0.47 |
| Change at Week 36: Social Functioning | -0.98 ± 0.50 | -0.84 ± 0.49 |
| Change at Week 36: Bodily Pain Score | -2.03 ± 0.53 | -0.58 ± 0.52 |
| Change at Week 36: Mental Health Score | -1.22 ± 0.51 | -0.32 ± 0.50 |
| Change at Week 36: Role Emotional Score | -1.80 ± 0.56 | -0.69 ± 0.55 |
| Change at Week 36: Vitality Score | -1.30 ± 0.50 | -0.15 ± 0.50 |
| Change at Week 36: General Health Perception Score | -0.98 ± 0.44 | -0.87 ± 0.43 |
| Change at Week 48: Physical Functioning | -0.46 ± 0.49 | -0.97 ± 0.48 |
| Change at Week 48: Role Physical Score | -0.88 ± 0.51 | -0.15 ± 0.50 |
| Change at Week 48: Social Functioning | -1.06 ± 0.53 | -0.55 ± 0.52 |
| Change at Week 48: Bodily Pain Score | -1.46 ± 0.54 | -0.71 ± 0.54 |
| Change at Week 48: Mental Health Score | -0.34 ± 0.54 | 0.12 ± 0.54 |
| Change at Week 48: Role Emotional Score | -0.83 ± 0.54 | -0.36 ± 0.54 |
| Change at Week 48: Vitality Score | -0.77 ± 0.52 | -0.25 ± 0.52 |
| Change at Week 48: General Health Perception Score | -0.43 ± 0.45 | -1.05 ± 0.44 |
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health perception. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were summarized aggregated to derive the two 2 component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher PCS/MCS indicated good health condition.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36: Physical Component Score | -1.42 ± 0.44 | -0.60 ± 0.43 |
| Change at Week 36: Mental Component Score | -1.25 ± 0.48 | -0.43 ± 0.47 |
| Change at Week 48: Physical Component Score | -0.83 ± 0.44 | -0.92 ± 0.43 |
| Change at Week 48: Mental Component Score | -0.65 ± 0.51 | 0.03 ± 0.50 |
WPAI is 6-question participant rated questionnaire to determine the impact of rheumatoid arthritis and yields 4 types of outcomes: absenteeism (work time missed), presenteeism (impairment while working), work productivity loss (overall work impairment), and daily activity impairment (activity impairment) for a period of 7 days prior to a visit. These 4 outcomes are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.
| percentage impairment | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36: Absenteeism | -1.39 ± 1.79 | -3.00 ± 1.69 |
| Change at Week 36: Daily activity impairment | 4.00 ± 1.35 | 0.81 ± 1.34 |
| Change at Week 36: Presenteeism | 3.68 ± 2.20 | 0.67 ± 2.07 |
| Change at Week 36: Work productivity loss | 3.03 ± 2.57 | 0.19 ± 2.41 |
| Change at Week 48: Absenteeism | -2.21 ± 1.70 | -1.69 ± 1.61 |
| Change at Week 48: Daily activity impairment | 2.86 ± 1.47 | 1.25 ± 1.46 |
| Change at Week 48: Presenteeism | 2.82 ± 2.78 | 3.72 ± 2.61 |
| Change at Week 48: Work productivity loss | 2.98 ± 3.09 | 5.45 ± 2.91 |
EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. 3 possible answers for mobility: 1=no problem in walking, 2=moderate problems in walking, 3= confined to bed; self-care: 1=no problem, 2=moderate problems, 3= unable to wash/dress; usual activities: 1=no problem, 2=moderate problems, 3= unable to do usual activities; pain and discomfort: 1=no pain or discomfort, 2=moderate pain or discomfort, 3= extreme pain or discomfort; anxiety and depression: 1=not anxious or depressed, 2=moderately anxious or depressed, 3= extremely anxious or depressed. The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36 | -0.05 ± 0.01 | -0.01 ± 0.01 |
| Change at Week 48 | -0.02 ± 0.01 | 0.00 ± 0.01 |
The FACIT-Fatigue scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (maximum fatigue) to 4 (no fatigue), higher scores indicate less fatigue. Total FACIT-fatigue score was obtained by addition of scores from 13 items, giving a possible overall range from 0 (maximum fatigue) to 52 (no fatigue). Higher FACIT-fatigue scores indicated lower level of fatigue, better participant status.
| units on a scale | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Change at Week 36 | -0.99 ± 0.43 | -0.80 ± 0.43 |
| Change at Week 48 | -0.34 ± 0.46 | -0.52 ± 0.45 |
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities.. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Percentage of participants with an improvement of at least 0.22 units in HAQ scores from baseline (Day 1) to Weeks 36 and 48 were reported in this outcome measure.
| percentage of participants | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|
| Week 36 | 67.05 | 77.07 |
| Week 48 | 68.56 | 75.19 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 52 (up to 28 days after last dose) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.
| Participants | Open Label: Tofacitinib 11 mg + Methotrexate | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|---|
| AEs | 362 | 107 | 109 |
| SAEs | 20 | 10 | 5 |
Abnormality criteria: Hemoglobin (Hb),Hematocrit,Erythrocytes(Ery): \<0.8\*LLN;Ery. Mean corpuscular volume \<0.9\*lower limit of normal (LLN), \>1.1\*upper limit of normal (ULN); Platelets:\<0.5\*LLN,\>1.75\*ULN;WBCs:\<0.6\*LLN,\>1.5\*ULN; Lymphocytes/WBCs, Neutrophils/WBCs:\<0.8\*LLN,\>1.2\* ULN;Basophils,Basophils/WBCs,Eosinophils,Eosinophils/WBCs,Monocytes, Monocytes/WBCs: \>1.2\*ULN;Prothrombin Time, Prothrombin Intl. Normalized Ratio:\>1.1\*ULN; ESR:\>1.5\*ULN; Bilirubin,Direct Bilirubin,Indirect Bilirubin: \>1.5\*ULN; Aspartate Aminotransferase (AT),Alanine AT,Gamma Glutamyl Transferase,Alkaline Phosphatase:\>3.0\*ULN; Protein, Albumin: \<0.8\*LLN, \>1.2x ULN; Blood Urea Nitrogen, Creatinine, Triglycerides: \>1.3\*ULN;HDL Cholesterol:\<0.8\*LLN;Sodium \<0.95\*LLN, \>1.05\*ULN;Potassium, Chloride, Calcium, Bicarbonate: \<0.9\*LLN, \>1.1\*ULN; Glucose: \<0.6\*LLN, \>1.5\*ULN; Creatine Kinase: \>2.0\*ULN; Cholesterol:\>1.3\*ULN;Specific Gravity:\<1.003;pH:\<4.5; urine glucose,Ketones,urine protein,urine Hb,WBCs Esterase: \>=1.
| Participants | Open Label: Tofacitinib 11 mg + Methotrexate | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|---|
| Number of Participants With Abnormal Laboratory Parameters | 682 | 263 | 263 |
Collected over Baseline (Day 1) up to Week 52. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label: Tofacitinib 11 mg + Methotrexate | 0/694 (0%) | 20/694 (2.9%) | 158/694 (22.8%) |
| Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | 0/264 (0%) | 10/264 (3.8%) | 24/264 (9.1%) |
| Double Blind: Tofacitinib 11mg + Methotrexate | 2/266 (0.8%) | 5/266 (1.9%) | 31/266 (11.7%) |
| Event | Open Label: Tofacitinib 11 mg + Methotrexate | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/694 | 1/264 | 2/266 |
| PneumoniaInfections and infestations | 3/694 | 1/264 | 0/266 |
| Umbilical herniaGastrointestinal disorders | 0/694 | 1/264 | 0/266 |
| OsteomyelitisInfections and infestations | 0/694 | 1/264 | 0/266 |
| Femur fractureInjury, poisoning and procedural complications | 1/694 | 1/264 | 0/266 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/694 | 1/264 | 0/266 |
| Mobility decreasedMusculoskeletal and connective tissue disorders | 0/694 | 1/264 | 0/266 |
| Adrenal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/694 | 1/264 | 0/266 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/694 | 1/264 | 0/266 |
| Nerve root compressionNervous system disorders | 0/694 | 1/264 | 0/266 |
| Event | Open Label: Tofacitinib 11 mg + Methotrexate | Double Blind: Tofacitinib 11 mg + Methotrexate Placebo | Double Blind: Tofacitinib 11mg + Methotrexate |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 35/694 | 5/264 | 7/266 |
| Upper respiratory tract infectionInfections and infestations | 33/694 | 4/264 | 6/266 |
| Alanine aminotransferase increasedInvestigations | 16/694 | 5/264 | 10/266 |
| NauseaGastrointestinal disorders | 20/694 | 0/264 | 0/266 |
| Urinary tract infectionInfections and infestations | 19/694 | 0/264 | 0/266 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/694 | 7/264 | 2/266 |
| BronchitisInfections and infestations | 0/694 | 3/264 | 7/266 |
| HeadacheNervous system disorders | 17/694 | 0/264 | 0/266 |
| HypertensionVascular disorders | 17/694 | 0/264 | 0/266 |
| DiarrhoeaGastrointestinal disorders | 16/694 | 0/264 | 0/266 |
Open-label phase safety analysis set (Safety-OL) included all participants who received at least 1 dose of Tofacitinib MR 11 mg plus Methotrexate during open-label phase.
| Age, Continuous(Years) | Open Label: Tofacitinib 11 mg + Methotrexate |
|---|---|
| Mean | 56.77 ± 11.83 |
| Sex: Female, Male(Participants) | Open Label: Tofacitinib 11 mg + Methotrexate |
|---|---|
| Female | 532 |
| Male | 162 |
| Ethnicity (NIH/OMB)(Participants) | Open Label: Tofacitinib 11 mg + Methotrexate |
|---|---|
| Hispanic or Latino | 59 |
| Not Hispanic or Latino | 635 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Open Label: Tofacitinib 11 mg + Methotrexate |
|---|---|
| Asian | 37 |
| Black or African American | 33 |
| White | 594 |
| Others | 30 |
Showing the first 100 of 136 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2016 to primary completion in Nov 2018, 26 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 26 months is close to that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tofacitinib · Methotrexate